Certolizumab Pegol
| 證據等級: L5 | 預測適應症: 6 個 |
目錄
Certolizumab Pegol: From Rheumatoid Arthritis to Rheumatoid Vasculitis
One-Sentence Summary
Certolizumab pegol is a PEGylated anti-TNF-α Fab fragment established for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and Crohn's disease. The TxGNN model predicts it may be effective for Rheumatoid Vasculitis, but the supporting evidence is thin and directionally mixed — 3 clinical trials (none testing this indication directly) and 8 publications, most of which describe anti-TNF-induced vasculitis rather than treatment benefit.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Rheumatoid arthritis (also established for axial spondyloarthritis, psoriatic arthritis, and Crohn's disease per literature evidence) |
| Predicted New Indication | Rheumatoid Vasculitis |
| TxGNN Prediction Score | 99.78% |
| Evidence Level | L4 |
| Norway Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on known information drawn from the supporting literature, certolizumab pegol is a PEGylated, Fc-free Fab fragment of a humanized monoclonal antibody that selectively neutralizes TNF-α; it is an established treatment for rheumatoid arthritis (RA), axial spondyloarthritis, psoriatic arthritis, and Crohn's disease.
Rheumatoid vasculitis is a recognized extra-articular complication of RA, and TNF-α is mechanistically implicated in the vascular inflammation seen in this condition — providing a plausible rationale for TxGNN to link certolizumab to this disease via shared pathway biology.
However, the literature retrieved for this candidate tells a more complicated story: of 8 publications, only one (PMID 34786446) reports certolizumab as a successful treatment for RA-associated vasculitis (leg ulcers). The remaining seven are adverse-event case reports and case series describing anti-TNF agents — including certolizumab itself — as a cause of vasculitis (leukocytoclastic vasculitis, hypocomplementemic urticarial vasculitis, medium-vessel vasculitis, rapidly progressive glomerulonephritis). This "paradoxical vasculitis" phenomenon is a known class effect of TNF inhibitors. The mechanistic direction of this prediction is therefore ambiguous rather than confirmatory.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT07138898 | Phase 2 | Not yet recruiting | 80 | Perioperative immunosuppressant management in RA patients undergoing shoulder arthroplasty; not focused on vasculitis treatment |
| NCT01579006 | N/A | Completed | 184 | Non-interventional observational study of tocilizumab (not certolizumab) in RA; only indirectly relevant |
| NCT05696106 | N/A | Unknown | 750,000 | Real-world study of biologic-induced immune-mediated inflammatory disease risk; relates to disease-induction risk, not therapeutic benefit |
No trial in this evidence pack directly tests certolizumab pegol for rheumatoid vasculitis.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 34786446 | 2021 | Case report | JAAD Case Reports | Certolizumab pegol used to treat leg ulcers due to rheumatoid vasculitis (only positive treatment case) |
| 36597972 | 2022 | Retrospective cohort | RMD Open | Long-term certolizumab pegol in uveitis due to immune-mediated inflammatory disease, n=80 (related IMID population, not vasculitis-specific) |
| 36418084 | 2022 | Review/Safety analysis | RMD Open | Comparative infection profile of immune-modulatory drugs from SmPC data |
| 31990069 | 2020 | Case report (ADR) | J Clin Pharm Ther | Hypocomplementemic urticarial vasculitis developed during certolizumab treatment for RA |
| 28405087 | 2017 | Case report (ADR) | Proc (Baylor Univ Med Cent) | Leukocytoclastic vasculitis as a drug reaction to certolizumab pegol |
| 41158918 | 2025 | Case report (ADR) | Cureus | Anti-TNF-related medium-vessel vasculitis in a seronegative RA patient switched to certolizumab |
| 32687015 | 2021 | Case report (ADR) | Mod Rheumatol Case Rep | Rapidly progressive glomerulonephritis after introduction of certolizumab pegol |
| 29610119 | 2018 | Case series (ADR) | Clin Med Res | Single-center experience of biologic agent-associated cutaneous adverse events |
7 of 8 publications describe anti-TNF-induced vasculitis as an adverse drug reaction, not a therapeutic effect.
Norway Market Information
Certolizumab pegol currently holds no market authorization in Norway (market status: Not Marketed, 0 authorizations on record). No product listings are available for this evidence pack.
Safety Considerations
Please refer to the package insert for safety information. (TFDA label warnings, contraindications, and DDI data are flagged as a Blocking-severity data gap in this evidence pack and have not yet been retrieved.)
Conclusion and Next Steps
Decision: Hold
Rationale: The evidence level is L4 with no trial directly testing certolizumab pegol for rheumatoid vasculitis, and the literature signal is predominantly the opposite of what is being proposed — most reports describe TNF inhibitors, including certolizumab, as inducing vasculitis rather than treating it. This is consistent with a known paradoxical anti-TNF class effect and does not currently support a repurposing hypothesis.
To proceed, the following is needed:
- TFDA/product label warnings and contraindications (currently a Blocking data gap)
- Confirmed mechanism-of-action documentation from DrugBank
- A prospective or controlled study specifically evaluating certolizumab efficacy in rheumatoid vasculitis (none currently exists)
- A pharmacovigilance review to clarify whether the paradoxical vasculitis signal represents a safety risk rather than a therapeutic opportunity before further investment
Note: This same evidence pack contains two higher-confidence, L1-level signals for certolizumab pegol — inflammatory spondylopathy and vertebral disease — both reflecting its already-established, guideline-supported use in axial spondyloarthritis/ankylosing spondylitis. If not already documented as approved indications, these merit a separate, dedicated evaluation rather than being treated as novel repurposing candidates.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.